Bladder Injections vs Nerve Stimulation: Comparing Advanced Overactive Bladder Therapies

The folder on the kitchen table has two leaflets in it. One shows a diagram of a bladder with small dots where a needle would go. The other shows a thin wire and a device the size of a wristwatch face, tucked above the hip. Beside them sits a bladder diary, three weeks of columns filled in with a pencil, and the honest tally is what brought the appointment forward: eleven trips to the bathroom on a good day, two changes of clothes on a bad one.

People facing the bladder injections vs nerve stimulation decision have usually already done the hard, unglamorous work. They have cut back on caffeine, learned pelvic floor exercises, timed their voids, and tried at least one tablet that either did not help enough or brought a dry mouth and constipation that outlasted the benefit.

This explainer walks through what each option actually involves, what the strongest comparative evidence shows, and which questions deserve a straight answer before anyone signs a consent form.

Why bladder injections vs nerve stimulation becomes the question

Overactive bladder, often shortened to OAB, is a pattern of sudden, hard-to-defer urges to urinate, usually with frequent daytime trips and waking at night, sometimes with leakage. It is a description of symptoms rather than a single disease. The bladder wall muscle, called the detrusor, contracts when the bladder is only partly full, and the brain’s usual ability to say “not yet” is overridden.

Guidelines from the NHS and Mayo Clinic describe a stepped approach. The first rung is behavioral: adjusting fluid timing, reducing bladder irritants such as caffeine, bladder training to stretch the interval between voids, and pelvic floor muscle exercises. The second rung is medicine, usually an anticholinergic (a class that blocks the nerve chemical acetylcholine at the bladder) or a beta-3 agonist (a class that helps the detrusor relax during filling).

The conversation about bladder injections vs nerve stimulation begins when those two rungs are not enough, or when the side effects of medicine are not tolerable. Both approaches are commonly grouped as third-line therapy. That label does not mean last resort; it means they carry more procedural involvement than a tablet and are reserved for people who have genuinely tried the earlier steps.

Before either is offered, a clinician will usually want to confirm the diagnosis. That can include a urine test to exclude infection, a check of how much urine stays behind after voiding (the post-void residual), a review of the bladder diary, and sometimes urodynamics, a set of pressure measurements taken while the bladder fills and empties. The purpose is to make sure the problem is truly detrusor overactivity and not, for example, an obstruction or a bladder that empties poorly, because both therapies behave differently in those situations.

How bladder botulinum toxin injections actually work

Botulinum toxin is a purified protein made by a bacterium. In tiny, controlled amounts it blocks the release of acetylcholine, the chemical messenger that tells a muscle to contract. Injected into the detrusor, it dampens the involuntary squeezes that create urgency and leakage, while the bladder still fills and, for most people, still empties.

The procedure itself is usually short. A cystoscope, a thin tube with a camera, is passed through the urethra into the bladder. Numbing gel or a local anesthetic instilled into the bladder is common; some centers use sedation or general anesthesia depending on patient preference and health. Through a fine needle passed along the scope, the clinician places a series of small injections around the inside of the bladder wall, deliberately avoiding the area near the ureter openings. Most people go home the same day, according to the NHS treatment overview.

The effect is not immediate. The toxin takes days to bind and quiet the nerve endings, so the first change in urgency is typically noticed within one to two weeks. Because the body slowly builds new nerve connections, the benefit wears off over time. Mayo Clinic and the NHS both describe the effect lasting for several months, after which the injection can be repeated if it helped and was tolerated.

Two features shape how people weigh this option. First, it is reversible by nature: if the bladder becomes too relaxed and does not empty well, that state passes as the toxin wears off. Second, that same relaxation is the main risk. A bladder that cannot empty fully may leave residual urine that raises the chance of infection or requires a catheter, a thin tube used to drain urine, for a period. Your care team will check emptying after the first injection for exactly this reason.

Sacral neuromodulation for overactive bladder and tibial nerve stimulation: how the two nerve options differ

“Nerve stimulation” covers two quite different procedures, and conflating them causes confusion.

Sacral neuromodulation is an implanted therapy. The sacral nerves leave the lower spine and carry signals between the bladder, the pelvic floor and the brain. A thin lead is placed through a small incision near the tailbone so that it rests alongside one of these nerves, usually the third sacral nerve. It connects to a small pulse generator implanted under the skin of the upper buttock. The device delivers continuous, low-level electrical pulses that most people feel as a faint tingling or not at all. The exact mechanism is still being studied, but the leading explanation is that the pulses modify the reflex arcs that trigger inappropriate detrusor contractions, rather than paralyzing the muscle.

Nearly all programs use a test phase first. A temporary lead is placed, sometimes in a clinic under local anesthetic and sometimes in an operating room, and connected to an external stimulator worn on a belt for a trial period, described by Mayo Clinic as typically lasting about two weeks. Only if the bladder diary improves meaningfully is the permanent generator implanted.

Percutaneous tibial nerve stimulation works on the same nerve pathways from a distance. The tibial nerve runs down the leg and shares roots with the sacral nerves. A very fine acupuncture-style needle is placed just above the inner ankle, a surface electrode goes on the foot, and a mild current runs for about 30 minutes. The NHS describes a course of weekly sessions, commonly around 12, followed by maintenance sessions if it helps. Nothing is implanted and there is no surgery, but the benefit depends on continuing to attend.

The two therefore sit at different points on a spectrum: one asks for a small operation and offers a set-and-forget device; the other asks for time and repeat visits and leaves nothing behind.

Bladder injections vs nerve stimulation: what the head-to-head evidence shows

Direct comparisons are rare in urology, which makes the ROSETTA trial (Refractory Overactive Bladder: Sacral Neuromodulation vs Botulinum Toxin Assessment), published in JAMA and indexed on PubMed, unusually valuable. It randomized women with severe urgency incontinence who had not responded to earlier treatment to either bladder botulinum toxin injection or sacral neuromodulation, then followed them for six months.

The headline: both groups improved substantially. Daily urgency incontinence episodes fell by a mean of 3.9 in the injection group and 3.3 in the neuromodulation group, a statistically significant but modest difference favoring injections. Complete resolution of leakage over the six months was reported in 20% of the injection group versus 4% of the neuromodulation group.

Safety told the other half of the story. Urinary tract infections occurred in 35% of women after injection compared with 11% after neuromodulation. Some injection recipients needed to pass a catheter themselves to empty: 8% at one month, falling to 4% at three months and 2% at six months. In the neuromodulation group, 3% needed a revision or removal of the device within the follow-up.

Feature	Bladder botulinum toxin injections	Sacral neuromodulation	Tibial nerve stimulation
Setting	Outpatient cystoscopy	Minor surgery, usually after a trial phase	Clinic visits, no incision
Anesthesia	Local, sedation or general	Local or general	None
How long one treatment lasts	Months, then repeated	Years on one battery, per device type	Weekly course, then maintenance
Most discussed risk	Infection, incomplete emptying	Lead movement, discomfort, revision surgery	Mild bruising or tingling at the site
Reversible	Yes, wears off	Device can be switched off or removed	Yes, stop attending

One trial cannot settle a personal decision. It excluded men, it studied a single dose level, and it measured six months. It is nonetheless the clearest evidence that this is a choice between two effective options with different trade-offs, not between something that works and something that does not.

Who is usually offered each option, and who is asked to wait

Eligibility is less about age or sex than about a handful of practical questions, and the answers push people toward one side or the other.

The first is emptying. Someone whose bladder already leaves a lot of urine behind after voiding is at higher risk of retention after injections, because the therapy relaxes the detrusor further. Mayo Clinic notes that people considering injections need to be willing and able to use a catheter if that happens. For a person with arthritis in the hands, poor vision or limited support at home, that requirement can be decisive, and nerve stimulation may be discussed first.

The second is infection history. Repeated urinary tract infections tend to make clinicians cautious about a therapy that raised infection rates in the ROSETTA trial, particularly in older adults for whom infection can trigger confusion or falls.

The third is imaging. Anyone likely to need regular MRI scans for another condition should raise this early, because implanted stimulators have specific scanning conditions that vary by device generation.

Nerve stimulation has its own gates. Sacral neuromodulation involves surgery and a foreign body, so uncontrolled diabetes, active skin infection near the implant site, or an inability to operate the handheld controller can lead to a recommendation to wait or choose otherwise. Tibial nerve stimulation asks for weekly attendance for roughly three months; if travel or work make that unrealistic, its benefit is unlikely to materialize.

People are also commonly asked to wait when the diagnosis is uncertain, when a urine infection is present at the time of assessment, during pregnancy, or when a reversible contributor such as constipation or a recently started medicine that irritates the bladder has not yet been addressed. Waiting in these situations is not a refusal; it is a way of making sure the right problem is being treated.

What the first days and weeks look like after bladder injections

The immediate aftermath is usually mild. Some stinging on urination, pink-tinged urine and a sense of urgency that briefly feels worse than before are common in the first day or two, because the bladder lining has been punctured in several places. Drinking normally rather than restricting fluids helps flush the bladder, and most people return to ordinary activity the following day, according to the NHS description of the procedure.

The effect builds gradually. Most people notice a change in urgency within one to two weeks, with the full benefit settling by around four weeks. This lag matters practically: a person who feels no different after three days has not failed the treatment.

The most important follow-up happens about two weeks after the injection, when many programs check how well the bladder empties. This is usually a quick bladder ultrasound after voiding. If the residual volume is high, the team will discuss intermittent self-catheterization, which means passing a thin, single-use catheter several times a day to drain the bladder. It sounds daunting; most people who need it learn the technique in a single teaching session, and in the ROSETTA trial the need fell steadily over six months as the toxin wore off.

Symptoms of infection, such as burning, cloudy or foul-smelling urine, fever or new low back pain, deserve a prompt call because infection was the most frequent adverse event in trial data.

Beyond the first month, the timeline is one of watching for return. When urgency begins creeping back, typically after several months, that is the signal to arrange a repeat. Clinicians generally space injections so that the previous dose has clearly worn off, and the interval tends to be individual. Keeping a simple diary during the fade helps the team judge timing without guesswork.

What the first days and weeks look like with nerve stimulation

The rhythm here is different: less about waiting for a chemical to act and more about adjusting settings and living with a device.

For sacral neuromodulation, the trial phase comes first. The temporary lead is taped in place and connected to an external stimulator. Over the trial period, which Mayo Clinic describes as usually lasting about two weeks, the person is asked to keep a bladder diary as carefully as they did before. Showering is often restricted to protect the dressing, and bending or twisting at the waist is limited so the lead does not shift. The team compares the diary with the baseline and, if the improvement is meaningful by their criteria, schedules the permanent implant.

After the permanent procedure, expect a small incision over the upper buttock and another near the tailbone. Soreness for one to two weeks is typical, and activities that stretch the area, such as heavy lifting, long cycling sessions or vigorous twisting, are usually paused for several weeks while the lead scars into place. Programming adjustments happen at follow-up visits; the sensation should be a faint tingle in the perineal area or not noticeable at all. A sharp, painful or leg-directed sensation means the settings or lead position need review.

For tibial nerve stimulation, there is no recovery in the surgical sense. Each visit lasts about half an hour, the needle is removed at the end, and people walk out and drive home. The NHS notes that improvement, when it comes, tends to appear gradually over the course of the weekly sessions rather than after the first one. Minor bruising or a tingling sensation at the ankle is the most common complaint.

Across both forms, patience during the first month is the theme: the diary, not a feeling on any single day, is what guides the next step.

Side effects and risks compared honestly

Every effective bladder therapy carries a shadow of its own mechanism. Understanding that pattern helps make risk information feel less like a warning label and more like a map.

Bladder botulinum toxin injections relax the detrusor. Their principal risks follow directly: incomplete emptying, the possible need for temporary catheterization, and urinary tract infection, which occurred in 35% of injection recipients versus 11% of neuromodulation recipients in the ROSETTA trial. Blood in the urine for a day or two is expected. Generalized weakness or swallowing difficulty is rare with bladder use but is always listed, because it reflects the toxin acting beyond the intended site, and it is one of the red flags covered later in this article.

Sacral neuromodulation carries surgical and device risks rather than physiological ones. Pain at the generator site, infection of the implant, lead migration causing loss of effect or unwanted sensations, and the need for revision surgery are the main concerns. In ROSETTA, 3% needed revision or removal within six months; over longer periods, batteries reach the end of life and need replacement, and leads can fail. Cleveland Clinic’s overview also notes that some people simply stop feeling benefit over time even with reprogramming.

Tibial nerve stimulation has the gentlest profile: minor bleeding or bruising at the ankle, transient tingling, and the inconvenience of repeat visits. Its limitation is durability rather than danger.

Neither therapy is thought to cause structural bladder damage when used as intended, and neither addresses stress incontinence, the leakage that happens with coughing or lifting, which has separate causes. If both types of leakage are present, your team may explain that one therapy will improve only part of the picture.

Consent conversations should cover all of this in plain language, and it is entirely reasonable to ask for the numbers behind any reassurance you are given.

How long do results last, and what does maintenance involve?

Durability is where the two approaches most clearly diverge, and it often decides the matter for people who dislike repeat procedures.

Injections are inherently temporary. Mayo Clinic and the NHS both describe the benefit lasting several months before symptoms return and the injection can be repeated. Because the toxin blocks nerve endings that the body eventually regrows, this fade is expected, not a sign that the treatment has stopped working. Some people find the interval between injections lengthens or shortens over the years; the reason is not fully understood. A minority develop antibodies that reduce the effect, though this is thought to be uncommon at bladder doses. Practically, maintenance means a repeat cystoscopy every several months for as long as the therapy is wanted, along with periodic checks of bladder emptying.

Sacral neuromodulation is designed for continuity. Once implanted and programmed, the device works around the clock. Maintenance involves recharging (for rechargeable generators, usually done at home by holding a charger over the skin for a set period each week) or, for non-rechargeable versions, surgery to replace the generator when the battery is depleted after a number of years that depends on the device and settings. Programming visits to fine-tune the stimulation are typical in the first months and then become occasional. If the effect fades, reprogramming or lead repositioning may restore it.

Tibial nerve stimulation needs the most ongoing effort relative to its invasiveness. After the initial weekly course, the NHS describes maintenance sessions at longer intervals, tailored to when symptoms begin to return. Stop attending and the benefit generally wanes over weeks to months.

None of these timelines is a promise. Bladder diaries kept at intervals are the honest measure, and the treating team uses them to decide whether to continue, adjust or reconsider.

Living with an implant: scans, security gates, travel and everyday life

People contemplating sacral neuromodulation tend to ask the same practical questions, and the answers are more reassuring than the word “implant” suggests.

MRI is the big one. Older generations of stimulator were incompatible with MRI or limited scans to the head. Newer devices are labeled as conditionally compatible for whole-body scanning under specified conditions, but the exact rules depend on the device model and the scanner. The safe habit is simple: carry the device identification card, tell every radiology department about the implant before booking, and let them check the manufacturer’s conditions. Never assume a scan is fine because a previous one was.

Airport security and shop anti-theft gates rarely cause a problem beyond occasionally setting off an alarm; the identification card explains the device. Some people prefer to switch the stimulator off with the handheld controller while passing through and back on afterward.

Everyday activity is largely unrestricted once the lead has settled. Swimming, walking, gardening and sexual activity are all compatible with a healed implant. High-impact contact sports or repeated deep bending in the first weeks are the usual cautions. Sitting for long periods is fine, though a few people notice generator-site discomfort on hard seats.

Travel requires only forethought: pack the charger and controller, keep them in hand luggage, and know how to reach the implanting team if the device stops working while away. Other medical procedures, particularly those using electrical cautery or diathermy, should be flagged in advance so the team can decide whether to switch the device off temporarily.

For bladder injections, none of this applies. There is nothing to carry, nothing to charge and nothing to declare. For some people that simplicity is the deciding factor; for others, the freedom from repeat cystoscopies outweighs the small administrative burden of a device.

Where these fit as third line overactive bladder treatment, and whether you can switch

Choosing one option does not close the door on the other. Because injections wear off and a stimulator can be turned off or removed, the pathway is more like a set of adjustable steps than a one-way corridor.

Switching from injections to nerve stimulation is straightforward: the person simply does not book a repeat, allows the toxin to wear off, and proceeds to a stimulation trial once the bladder has returned to its baseline behavior. Moving in the other direction is equally possible; a stimulator can be switched off during a period of injections, or removed if a person decides they prefer a non-device approach.

Combining the two is done in some centers for people whose response to one is partial, but the evidence base for combination is thin and mostly observational. Anyone offered it should ask what the expected added benefit is and how it will be measured.

It also helps to remember what sits alongside third-line therapy rather than beneath it. Bladder training, fluid management and pelvic floor work remain useful even after a procedure; they are not abandoned. Medicines are sometimes continued at a lower level or restarted if a procedure gives partial relief, always at the prescribing clinician’s discretion. Absorbent products and scheduled voiding are legitimate parts of a plan, not admissions of failure.

At the far end of the pathway, for a small number of people with severe symptoms that resist everything above, surgical options such as bladder augmentation exist. They are major operations with lifelong consequences and are rarely needed today precisely because injections and neuromodulation have filled the gap between medicines and surgery.

The message for someone weighing the two is therefore reassuring: this is a decision that can be revisited. What matters is making the first choice with a clear diary, a clear understanding of the trade-offs and a team that will reassess rather than defend an earlier plan.

What people often get wrong about bladder injections and nerve stimulation

“The injections paralyze the bladder.” They weaken involuntary contractions; voluntary voiding continues for most people. Incomplete emptying happens in a minority and fades as the effect wears off, as ROSETTA’s falling catheterization figures show.

“Nerve stimulation is like a pacemaker for the bladder.” The comparison is tempting but misleading. A pacemaker triggers heartbeats; sacral neuromodulation does not make the bladder contract. It modulates the signaling that produces inappropriate urgency.

“A device means major surgery.” Sacral neuromodulation is a minor procedure with small incisions, often done as a day case, and it is preceded by a removable trial. Tibial stimulation involves no incision at all.

“If it does not work in the first week, it has failed.” Both therapies work on a lag: injections build over one to two weeks, stimulation over the trial period or the course of sessions. Diaries, not first impressions, judge success.

“These treatments fix all leakage.” They target urgency incontinence. Stress incontinence from coughing, sneezing or lifting has a different mechanism and is not addressed by either.

“Once you start injections you are stuck with them.” The effect wears off. Stopping is as simple as not booking the next one.

“Nerve stimulation is only for people who cannot have injections.” In the strongest direct comparison, both improved symptoms substantially. Many people choose neuromodulation first because they prefer fewer procedures or want to avoid catheterization risk.

“An implant rules out MRI forever.” Conditions vary by device, and many current devices permit scanning under specified rules. The right answer is device-specific and comes from the implanting team and radiology, not from a general assumption.

“Older adults should not have these.” Age alone is not a barrier. Frailty, ability to manage a catheter or controller, and infection risk are the actual considerations.

Questions to ask your care team before deciding

A good consultation should leave you able to explain the choice to someone else in your own words. These questions help get there.

• How confident are you that my symptoms are caused by detrusor overactivity rather than another problem, and what tests support that?
• How much urine is left in my bladder after I void now, and how does that affect my risk of needing a catheter after injections?
• If I did need to self-catheterize, who would teach me, how quickly, and what support exists if I struggle?
• How many urinary infections have I had in the past year, and does that change which option you would suggest?
• For nerve stimulation, what does the trial phase involve here, and what improvement in my diary would count as a successful trial?
• Which device would be used, and what are its MRI conditions and battery expectations?
• What is the plan if the first choice gives partial relief: adjust, repeat, add, or switch?
• How will we measure whether this is working, and when will we review it?
• What happens to my current bladder medicine: continue, reduce, or stop, and who decides?
• Are there reasons specific to my health, such as pregnancy plans, other surgeries or mobility, that make one option safer for me?
• What are the red-flag symptoms I should call about, and whom do I call out of hours?

Bring the bladder diary. It is the single most useful document in the room, more informative than any description of how the week “felt.” Bring a list of current medicines too, including over-the-counter ones and supplements, since some can worsen urgency or interact with sedation.

If two clinicians offer different first choices, that is not a sign that one is wrong. It usually reflects genuine equipoise in the evidence and differing weights on infection risk versus surgery. Ask each to explain why, then decide which set of trade-offs you would rather live with.

When to call your doctor

Most of what follows either procedure is mild and expected: brief stinging, pinkish urine, a sore incision or ankle, a few days of unsettled urgency. A handful of signs mean the same day, not the next appointment.

After bladder injections, call promptly if you cannot pass urine at all, or can pass only small dribbles with a full, painful lower abdomen; this may be acute retention and needs a catheter. Call about fever, chills, cloudy or foul-smelling urine, new pain in the flank or lower back, or blood in the urine that is heavy or continues beyond two days. Seek urgent care for difficulty swallowing, blurred or double vision, drooping eyelids, slurred speech, or weakness spreading beyond the pelvis; these are very rare with bladder use but signal the toxin acting outside the intended site.

After sacral neuromodulation, call if the incision becomes increasingly red, hot, swollen or leaks fluid, if you develop fever, or if the stimulation suddenly turns painful, shoots down a leg, or disappears altogether, which can indicate lead movement. New numbness, weakness in the legs or loss of bowel control after the procedure warrants urgent assessment.

After tibial nerve stimulation, problems are unusual, but spreading redness, swelling or persistent bleeding at the ankle should be reported.

For anyone with a bladder condition, regardless of treatment, seek same-day care for a urinary infection accompanied by confusion, shaking chills or vomiting, particularly in older adults, and for any sudden inability to urinate.

Keep the contact number for your urology team where you can find it, and use it. Clinicians would far rather hear about a false alarm than miss retention or infection that was allowed to build for a weekend. Every decision about what to do next, including whether to repeat, adjust or change therapy, belongs with the team who knows your history.

Frequently asked questions

Which is better for overactive bladder, bladder injections or nerve stimulation?

Neither is universally better; the strongest direct comparison found both reduced urgency incontinence substantially. Injections produced a slightly larger reduction in leakage episodes but more urinary infections and a temporary need for catheterization in some people, while sacral neuromodulation carried surgical and device risks instead. The better option depends on how well your bladder empties, your infection history, your willingness to have repeat procedures or an implant, and your team’s assessment.

How long do bladder botulinum toxin injections last?

The effect typically lasts several months, with Mayo Clinic and the NHS describing benefit for roughly six months before symptoms gradually return. Onset takes one to two weeks. Because the body regrows the nerve endings the toxin blocks, fading is expected rather than a sign of failure, and the injection can be repeated once the previous effect has clearly worn off. The exact interval varies from person to person.

What is sacral neuromodulation for overactive bladder and does it involve surgery?

Sacral neuromodulation is an implanted therapy that delivers low-level electrical pulses to a sacral nerve near the tailbone to calm the signaling that causes urgency. It does involve minor surgery, usually with small incisions and often as a day case, but nearly all programs start with a removable trial lead worn for about two weeks. The permanent pulse generator is placed only if the bladder diary shows meaningful improvement during the trial.

Does tibial nerve stimulation for bladder problems hurt?

Most people describe a mild tingling or tapping sensation in the foot rather than pain. A very fine needle is placed just above the inner ankle and a gentle current runs for about 30 minutes; bruising or brief soreness at the site is the most common complaint. The NHS describes a course of weekly sessions, commonly around 12, followed by maintenance visits if it helps. There is no incision, no anesthesia and no recovery period.

Will I need a catheter after bladder injections?

Most people do not, but a minority temporarily cannot empty fully and are taught intermittent self-catheterization, which means passing a thin single-use tube several times a day. In the ROSETTA trial this affected 8% of women at one month, falling to 2% by six months as the toxin wore off. Your team will check how much urine remains after voiding about two weeks after the injection to catch this early.

Can I have an MRI with a sacral nerve stimulator?

It depends on the specific device. Many current stimulators are labeled as MRI-conditional, meaning scans are permitted under defined conditions, while older models had stricter limits. Always carry your device identification card, tell the radiology department about the implant before any scan is booked, and let them confirm the manufacturer’s conditions. Never assume a scan is safe because a previous one was.

Is third line overactive bladder treatment a last resort?

No. Third-line simply means these options come after behavioral measures and medicines have been tried, because they involve a procedure. Both bladder injections and nerve stimulation are established, guideline-supported therapies used by many people whose symptoms did not respond to tablets or who could not tolerate side effects. They are also reversible, and moving between them is possible, so choosing one does not close off the other.

Can bladder injections and nerve stimulation be combined?

Some centers combine them for people with a partial response to one therapy, but the evidence for combination is limited and mostly observational rather than from randomized trials. If combination is proposed, it is reasonable to ask what added benefit is expected, how it will be measured with a bladder diary, and whether the extra infection or procedural risk is justified. The decision rests with your treating team.

Do these treatments help stress incontinence too?

No. Both target urgency incontinence caused by involuntary bladder muscle contractions. Stress incontinence, the leakage that happens with coughing, sneezing, laughing or lifting, has a different mechanism involving the urethra and pelvic floor, and neither injections nor nerve stimulation address it. People with mixed incontinence should expect only the urgency component to improve and may need a separate plan for the stress component.

What if my first choice stops working?

Both approaches allow a change of course. If injections lose effect, the interval or plan can be reviewed, or you can let the toxin wear off and try nerve stimulation. If a stimulator’s benefit fades, reprogramming or lead repositioning may restore it, and the device can be switched off or removed. A fresh bladder diary is the tool your team will use to decide whether to adjust, repeat or switch.

References

• NHS: Urinary incontinence, treatment
• Cleveland Clinic: Overactive bladder
• MedlinePlus: Overactive bladder

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.